University of Newcastle. New South Wales, Australia.
University of Western Australia, Crawley, Perth, Australia.
Br J Clin Pharmacol. 2019 Oct;85(10):2198-2204. doi: 10.1111/bcp.13979. Epub 2019 Jun 20.
Drug development for cancer chemotherapy has an interesting history. A mix of serendipity, animal, cell line, and standard pharmacological principles of dose, dose-response, dose-concentration, dose intensity and combination therapies have been used to develop optimal dosing schedules. However in practice, significant gaps in the translation of preclinical to clinical dosing schedules persist, and clinical development has instead moved to new drug development. A older chemotherapies are still the backbone of most solid tumour schedules, therapeutic drug monitoring has emerged as a method for optimising the dose for individual patients.
癌症化疗药物的开发有着有趣的历史。机遇、动物、细胞系和标准药理学剂量、剂量反应、剂量浓度、剂量强度和联合治疗的原则的结合，被用于制定最佳的给药方案。然而，在实践中，从临床前到临床给药方案的转化仍存在显著差距，临床开发已转向新药开发。一些较老的化疗药物仍然是大多数实体瘤方案的基础，治疗药物监测已成为优化个体患者剂量的一种方法。
